Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2010-11-26
pubmed:abstractText
The aberrant overexpression of Wilms tumor 1 (WT1) in myeloid leukemia plays an important role in blast cell survival and resistance to chemotherapy. High expression of WT1 is also associated with relapse and shortened disease-free survival in patients. However, the mechanisms by which WT1 expression is regulated in leukemia remain unclear. Here, we report that heat shock protein 90 (Hsp90), which plays a critical role in the folding and maturation of several oncogenic proteins, associates with WT1 protein and stabilizes its expression. Pharmacologic inhibition of Hsp90 resulted in ubiquitination and subsequent proteasome-dependant degradation of WT1. RNAi-mediated silencing of WT1 reduced the survival of leukemia cells and increased the sensitivity of these cells to chemotherapy and Hsp90 inhibition. Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2. Collectively, our studies identify WT1 as a novel Hsp90 client and support the crucial role for the WT1-Hsp90 interaction in maintaining leukemia cell survival. These findings have significant implications for developing effective therapies for myeloid leukemias and offer a strategy to inhibit the oncogenic functions of WT1 by clinically available Hsp90 inhibitors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4591-9
pubmed:meshHeading
pubmed-meshheading:20651072-Animals, pubmed-meshheading:20651072-Antineoplastic Agents, Phytogenic, pubmed-meshheading:20651072-Apoptosis, pubmed-meshheading:20651072-Benzoquinones, pubmed-meshheading:20651072-Cell Line, Tumor, pubmed-meshheading:20651072-Etoposide, pubmed-meshheading:20651072-Female, pubmed-meshheading:20651072-Gene Expression Regulation, Leukemic, pubmed-meshheading:20651072-Gene Silencing, pubmed-meshheading:20651072-HSP90 Heat-Shock Proteins, pubmed-meshheading:20651072-Humans, pubmed-meshheading:20651072-Lactams, Macrocyclic, pubmed-meshheading:20651072-Leukemia, Myeloid, pubmed-meshheading:20651072-Mice, pubmed-meshheading:20651072-Mice, SCID, pubmed-meshheading:20651072-Proteasome Endopeptidase Complex, pubmed-meshheading:20651072-Protein Interaction Domains and Motifs, pubmed-meshheading:20651072-Protein Structure, Tertiary, pubmed-meshheading:20651072-Triazoles, pubmed-meshheading:20651072-WT1 Proteins
pubmed:year
2010
pubmed:articleTitle
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
pubmed:affiliation
Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. bansals@uthscsa.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural